It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field allied to his scientific training, Tim is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today Tim's principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Court and Unified Patents Court principally to innovator biotech and pharma companies. Tim has advised on numerous blockbuster treatments including monoclonal antibody therapies and other biologics, as well as other innovative technologies.
Tim enjoys helping his clients understand, enforce and defend their IP rights and minimise their risks. The approach taken to this work is always collaborative, often working as part of a multi-jurisdictional team he relishes the challenge of forming and deploying creative legal and commercial strategies.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
Helping you succeed in tomorrow's world
I enjoy developing and supporting the next generation of lawyers and entrepreneurs. I take pleasure from regularly lecturing, teaching, and working with start-ups and spin-outs to help them understand how to protect their innovations and minimise IP risks.
Advised Amgen on the commerciation of its eculizumab biosimilar (BEKEMV®) in the UK High Court, UPC litigation and pan-European strategy.
Advised Santen on the protection and enforcement of its tafluprost (TAFLOTAN®) patent rights in the UK and across Europe.
Represented Anstar to defend its photoinitiator chemical business in UK High Court patent infringement proceedings.
Advised a large pharmaceutical company in relation to patent rights in direct oral anticoagulants (DOACs).
Represented Block, Inc. (formerly Square, Inc.) defending High Court litigation concerning IP rights in bitcoin.
Advised Eurosemillas SA in relation to the UK aspects of its plant variety rights in a multinational dispute.
Supported Dialight plc in the renegotiation of its patent licence from Signify and the commercialisation of its own patent portfolio.
Advised A-Gas on its IP strategy and enforcement.
Insights
Unitary Patents and the Unified Patent Court: FAQs
Future IP issues relating to data-driven business models
Data-driven business models: the role of legal teams in delivering success | Key findings
Data-driven business models: the role of legal teams in delivering success | Report
IP basics: what to think about when entering the UK and EU markets (trade marks, copyright, designs)
Russia Retaliates Against Sanctions by Curtailing Foreign Owners’ IP rights
The Russian government has responded to western sanctions with new legislation designed to undermine the intellectual property (IP) rights of...